Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)

Background: This study compared the efficacy, safety, and immunogenicity of insulin aspart biosimilar/follow-on biologic product SAR341402 (SAR-Asp) with originator insulin aspart-NovoLog(®)/NovoRapid(®) (NN-Asp) in people with type 1 diabetes (T1D) or type 2 diabetes (T2D) treated with multiple dai...

Descripción completa

Detalles Bibliográficos
Autores principales: Garg, Satish K., Wernicke-Panten, Karin, Wardecki, Marek, Kramer, Daniel, Delalande, Francois, Franek, Edward, Sadeharju, Karita, Monchamp, Travis, Mukherjee, Bhaswati, Shah, Viral N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987634/
https://www.ncbi.nlm.nih.gov/pubmed/31804851
http://dx.doi.org/10.1089/dia.2019.0382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987634/
https://www.ncbi.nlm.nih.gov/pubmed/31804851
http://dx.doi.org/10.1089/dia.2019.0382

Ejemplares similares